Von dem Buch Benefit-Risk Assessment of Medicines haben wir 3 gleiche oder sehr ähnliche Ausgaben identifiziert!
Falls Sie nur an einem bestimmten Exempar interessiert sind, können Sie aus der folgenden Liste jenes wählen, an dem Sie interessiert sind:
100%: James Leong/ Sam Salek/ Stuart Walker: Benefit-Risk Assessment of Medicines (ISBN: 9783319367675) in Englisch, Taschenbuch.Nur diese Ausgabe anzeigen…
100%: James Leong/ Sam Salek/ Stuart Walker: Benefit-Risk Assessment of Medicines (ISBN: 9783319158044) 2015, in Englisch, Broschiert.Nur diese Ausgabe anzeigen…
64%: Stuart Walker/ Sam Salek/ James Leong: Benefit-Risk Assessment of Medicines (ISBN: 9783319158051) 2015, in Englisch, Taschenbuch.Nur diese Ausgabe anzeigen…
Benefit-Risk Assessment of Medicines - 14 Angebote vergleichen
| Preise | 2016 | 2019 | 2020 |
|---|---|---|---|
| Schnitt | Fr. 62.78 (€ 64.20)¹ | Fr. 83.60 (€ 85.49)¹ | Fr. 83.60 (€ 85.49)¹ |
| Nachfrage |
1
Symbolbild
Benefit-Risk Assessment of Medicines (2016)
DE NW RPISBN: 9783319367675 bzw. 3319367676, in Deutsch, Springer International Publishing AG, neu, Nachdruck.
Von Händler/Antiquariat, PBShop [61989342], Secaucus, NJ, U.S.A.
New Book.Shipped from US within 10 to 14 business days.THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
New Book.Shipped from US within 10 to 14 business days.THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
2
Symbolbild
Benefit-Risk Assessment of Medicines (2016)
DE NW RPISBN: 9783319367675 bzw. 3319367676, in Deutsch, Springer International Publishing AG, neu, Nachdruck.
Von Händler/Antiquariat, Books2Anywhere [190245], Fairford, GLOS, United Kingdom.
New Book. Delivered from our US warehouse in 10 to 14 business days. THIS BOOK IS PRINTED ON DEMAND.Established seller since 2000.
New Book. Delivered from our US warehouse in 10 to 14 business days. THIS BOOK IS PRINTED ON DEMAND.Established seller since 2000.
3
Symbolbild
Benefit-Risk Assessment of Medicines. The Development and Application of a Universal Framework for Decision-Making and Effective Communication (2016)
DE PB NWISBN: 9783319367675 bzw. 3319367676, in Deutsch, Adis, Taschenbuch, neu.
Von Händler/Antiquariat, Herb Tandree Philosophy Books [17426], Stroud, GLOS, United Kingdom.
9783319367675 This listing is a new book, a title currently in-print which we order directly and immediately from the publisher.
9783319367675 This listing is a new book, a title currently in-print which we order directly and immediately from the publisher.
4
Symbolbild
Benefit-Risk Assessment of Medicines. The Development and Application of a Universal Framework for Decision-Making and Effective Communication (2015)
DE HC USISBN: 9783319158044 bzw. 331915804X, in Deutsch, Adis, gebundenes Buch, gebraucht.
Von Händler/Antiquariat, Herb Tandree Philosophy Books [17426], Stroud, United Kingdom.
9783319158044 Hardback, This listing is a new book, a title currently in-print which we order directly and immediately from the publisher.
9783319158044 Hardback, This listing is a new book, a title currently in-print which we order directly and immediately from the publisher.
5
Symbolbild
Benefit-Risk Assessment of Medicines: The Development and Application of a Universal Framework for Decision-Making and Effective Communication (Hardback) (2015)
DE HC NWISBN: 9783319158044 bzw. 331915804X, in Deutsch, Springer International Publishing AG, Switzerland, gebundenes Buch, neu.
Lieferung aus: Vereinigtes Königreich Grossbritannien und Nordirland, Versandkostenfrei.
Von Händler/Antiquariat, The Book Depository EURO [60485773], London, United Kingdom.
Language: English Brand New Book. Over the past decade pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view to developing a structured systematic standardized approach. In view of this a universal framework together with an appropriate documentation system for recording benefit-risk decisions has been developed and applied and is a valuable addition to the Benefit-Risk Toolbox. The opportunity to examine the implementation of this approach by several regulatory authorities places this book in a unique position with the potential to positively contribute to the ongoing debate in this area. The field of benefit-risk assessment continues to evolve at a rapid pace due to political and societal pressure, as is also reflected in the recent FDA PUDFA agreement as well as in the EMA 2015 Roadmap. Therefore, this is not an attempt to provide a comprehensive and complete account of the current benefit-risk assessment environment; rather, the strength of this book is that it provides an evaluation of some current approaches to the benefit-risk assessment of medicines and outlines the development of a new universal framework. It also demonstrates how a number of mature agencies have implemented this universal framework together with the methodology for documenting their benefit-risk decisions. In addition, it also reviews current publicly available documents together with their strengths and weaknesses in communicating benefit-risk decisions to stakeholders.
Von Händler/Antiquariat, The Book Depository EURO [60485773], London, United Kingdom.
Language: English Brand New Book. Over the past decade pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view to developing a structured systematic standardized approach. In view of this a universal framework together with an appropriate documentation system for recording benefit-risk decisions has been developed and applied and is a valuable addition to the Benefit-Risk Toolbox. The opportunity to examine the implementation of this approach by several regulatory authorities places this book in a unique position with the potential to positively contribute to the ongoing debate in this area. The field of benefit-risk assessment continues to evolve at a rapid pace due to political and societal pressure, as is also reflected in the recent FDA PUDFA agreement as well as in the EMA 2015 Roadmap. Therefore, this is not an attempt to provide a comprehensive and complete account of the current benefit-risk assessment environment; rather, the strength of this book is that it provides an evaluation of some current approaches to the benefit-risk assessment of medicines and outlines the development of a new universal framework. It also demonstrates how a number of mature agencies have implemented this universal framework together with the methodology for documenting their benefit-risk decisions. In addition, it also reviews current publicly available documents together with their strengths and weaknesses in communicating benefit-risk decisions to stakeholders.
6
Benefit-Risk Assessment of Medicines (2015)
~EN PB NW RPISBN: 3319367676 bzw. 9783319367675, vermutlich in Englisch, Springer International Publishing, Taschenbuch, neu, Nachdruck.
Benefit-Risk Assessment of Medicines ab 85.49 € als Taschenbuch: The Development and Application of a Universal Framework for Decision-Making and Effective Communication. Softcover reprint of the original 1st ed. 2015. Aus dem Bereich: Bücher, Wissenschaft, Medizin,.
7
Symbolbild
Benefit-Risk Assessment of Medicines: The Development and Application of a Universal Framework for Decision-Making and Effective Communication (2016)
DE PB NW RPISBN: 9783319367675 bzw. 3319367676, in Deutsch, ADIS, Taschenbuch, neu, Nachdruck.
Lieferung aus: Deutschland, Versandkostenfrei.
Von Händler/Antiquariat, English-Book-Service Mannheim [1048135], Mannheim, Germany.
This item is printed on demand for shipment within 3 working days.
Von Händler/Antiquariat, English-Book-Service Mannheim [1048135], Mannheim, Germany.
This item is printed on demand for shipment within 3 working days.
8
Benefit-Risk Assessment of Medicines (2015)
DE NWISBN: 9783319158044 bzw. 331915804X, in Deutsch, Springer-Verlag GmbH, neu.
Lieferung aus: Deutschland, Versandkostenfrei.
Sparbuchladen, [3602074].
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Sparbuchladen, [3602074].
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
9
Benefit-Risk Assessment of Medicines (2015)
~EN HC NWISBN: 331915804X bzw. 9783319158044, vermutlich in Englisch, Springer-Verlag GmbH, gebundenes Buch, neu.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
10
Benefit-Risk Assessment of Medicines - The Development and Application of a Universal Framework for Decision-Making and Effective Communication (2015)
~EN HC NWISBN: 9783319158044 bzw. 331915804X, vermutlich in Englisch, Springer-Verlag Gmbh, gebundenes Buch, neu.
Lieferung aus: Deutschland, Free shipping.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Lade…